MicroRNA-451a, MicroRNA-34a-5p, and MicroRNA-221-3p As Predictors of Response to Antidepressant Treatment

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2018 May 24

PMID 29791588

Citations 38

Authors

Wei-Hong Kuang

Zai-Quan Dong

Lian-Tian Tian

Jin Li

Affiliations

Soon will be listed here.

Abstract

Aberrant expression of microRNAs (miRNAs) has been shown to be involved in early observations of depression. The aim of this study was to determine if serum levels of miRNA-451a, miRNA-34a-5p, and miRNA-221-3p can serve as indicators of disease progression or therapeutic efficacy in depression. We collected data from 84 depressed patients and 78 control volunteers recruited from the medical staff at the West China Hospital. Depression severity was rated using the 24-item Hamilton Depression Scale (HAMD). Serum miRNA-451a, miRNA-34a-5p, and miRNA-221-3p levels were determined in samples from the depressed patients before and 8 weeks after antidepressant treatment as well as in samples from controls. Compared with the controls, the patients had lower miRNA-451a levels, higher miRNA-34a-5p and miRNA-221-3p levels, and increased HAMD scores whether they underwent antidepressant treatment or not. Eight weeks after antidepressant treatment, the patients exhibited increased miRNA-451a levels, decreased miRNA-34a-5p and miRNA-221-3p levels, and reduced HAMD scores. The serum level of miRNA-451a was negatively correlated with HAMD scores of the patients, while the serum levels of miRNA-34a-5p and miRNA-221-3p were positively correlated with HAMD scores whether the patients underwent antidepressant treatment or not. Paroxetine was markedly effective in 50 patients who also displayed an increased level of miRNA-451a but reduced levels of miRNA-34a-5p and miRNA-221-3p. In contrast, paroxetine was moderately effective or ineffective in 34 patients. In conclusion, depressed patients had lower serum miRNA-451a but higher serum miRNA-34a-5p and miRNA-221-3p, and these miRNAs are potential predictors of the efficacy of antidepressants.

Citing Articles

The RNA Demethyltransferase FTO Regulates Ferroptosis in Major Depressive Disorder.

Meng K, Liu Z, Yu Y, Zhang E, Yu X, Meng P Int J Mol Sci. 2025; 26(3).

PMID: 39940841 PMC: 11817352. DOI: 10.3390/ijms26031075.

Exercise, Neuroprotective Exerkines, and Parkinson's Disease: A Narrative Review.

Mitchell A, Bliss R, Church F Biomolecules. 2024; 14(10).

PMID: 39456173 PMC: 11506540. DOI: 10.3390/biom14101241.

Epigenetic mechanisms of rapid-acting antidepressants.

Inserra A, Campanale A, Rezai T, Romualdi P, Rubino T Transl Psychiatry. 2024; 14(1):359.

PMID: 39231927 PMC: 11375021. DOI: 10.1038/s41398-024-03055-y.

Perspective on adolescent psychiatric illness and emerging role of microRNAs as biomarkers of risk.

Morgunova A, Teixeira M, Flores C J Psychiatry Neurosci. 2024; 49(4):E282-E288.

PMID: 39209460 PMC: 11374446. DOI: 10.1503/jpn.240072.

Chamakioti M, Chrousos G, Kassi E, Vlachakis D, Yapijakis C Int J Mol Sci. 2024; 25(15).

PMID: 39125827 PMC: 11311345. DOI: 10.3390/ijms25158256.

References

Bech P . The responsiveness of the different versions of the Hamilton Depression Scale. World Psychiatry. 2015; 14(3):309-10. PMC: 4592652. DOI: 10.1002/wps.20248. View

Li L, Yuan L, Luo J, Gao J, Guo J, Xie X . MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2012; 13(2):109-17. DOI: 10.1007/s10238-012-0186-5. View

Dwivedi Y . Evidence demonstrating role of microRNAs in the etiopathology of major depression. J Chem Neuroanat. 2011; 42(2):142-56. PMC: 3163781. DOI: 10.1016/j.jchemneu.2011.04.002. View

Krishnan V, Nestler E . The molecular neurobiology of depression. Nature. 2008; 455(7215):894-902. PMC: 2721780. DOI: 10.1038/nature07455. View

Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D . Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2012; 23(7):602-11. DOI: 10.1016/j.euroneuro.2012.06.013. View

Drevets W, Price J, Furey M . Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008; 213(1-2):93-118. PMC: 2522333. DOI: 10.1007/s00429-008-0189-x. View

Liu Z, Miao T, Feng T, Jiang Z, Li M, Zhou L . miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor. Biomed Res Int. 2015; 2015:207684. PMC: 4486513. DOI: 10.1155/2015/207684. View

Krishnadas R, Cavanagh J . Depression: an inflammatory illness?. J Neurol Neurosurg Psychiatry. 2012; 83(5):495-502. DOI: 10.1136/jnnp-2011-301779. View

Dwivedi Y . Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications. Dialogues Clin Neurosci. 2014; 16(1):43-61. PMC: 3984890. View

10.

Wibrand K, Pai B, Siripornmongcolchai T, Bittins M, Berentsen B, Ofte M . MicroRNA regulation of the synaptic plasticity-related gene Arc. PLoS One. 2012; 7(7):e41688. PMC: 3406043. DOI: 10.1371/journal.pone.0041688. View

11.

Greenhalgh T . WHO/WONCA report - Integrating Mental Health in Primary Care: A Global Perspective. London J Prim Care (Abingdon). 2015; 2(1):81-2. PMC: 4453694. DOI: 10.1080/17571472.2009.11493254. View

12.

Kim Y, Lee H, Won S, Park E, Lee H, Lee B . Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 31(1):78-85. DOI: 10.1016/j.pnpbp.2006.06.024. View

13.

Liu B, Luo L, Liu X, Geng D, Liu Q, Yi L . 7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. Psychopharmacology (Berl). 2014; 232(3):541-50. DOI: 10.1007/s00213-014-3690-3. View

14.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

15.

Beveridge N, Cairns M . MicroRNA dysregulation in schizophrenia. Neurobiol Dis. 2011; 46(2):263-71. DOI: 10.1016/j.nbd.2011.12.029. View

16.

Dennis C, Dowswell T . Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. Cochrane Database Syst Rev. 2013; (7):CD006795. PMC: 11536339. DOI: 10.1002/14651858.CD006795.pub3. View

17.

Cheng H, Papp J, Varlamova O, Dziema H, Russell B, Curfman J . microRNA modulation of circadian-clock period and entrainment. Neuron. 2007; 54(5):813-29. PMC: 2590749. DOI: 10.1016/j.neuron.2007.05.017. View

18.

Belmaker R, Agam G . Major depressive disorder. N Engl J Med. 2008; 358(1):55-68. DOI: 10.1056/NEJMra073096. View

19.

Camkurt M, Acar S, Coskun S, Gunes M, Gunes S, Yilmaz M . Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls. J Psychiatr Res. 2015; 69:67-71. DOI: 10.1016/j.jpsychires.2015.07.023. View

20.

Kessler R, Bromet E . The epidemiology of depression across cultures. Annu Rev Public Health. 2013; 34:119-38. PMC: 4100461. DOI: 10.1146/annurev-publhealth-031912-114409. View